Genmab reports DARZALEX net sales of $3.67 billion in Q3 2025

Genmab A/S (NASDAQ: GMAB) announced that worldwide net sales of DARZALEX (daratumumab) totaled $3.672 billion in the third quarter of 2025, as reported by Johnson & Johnson.

The sales figure includes both intravenous and subcutaneous formulations of the cancer treatment. Net sales in the U.S. reached $2.088 billion, while international markets generated $1.584 billion in revenue.

Genmab receives royalties on worldwide net sales of DARZALEX under an exclusive license agreement with Johnson & Johnson's Janssen Biotech unit, which handles development, manufacturing and commercialization of the drug. The subcutaneous version is marketed as DARZALEX FASPRO in the United States.

The Copenhagen-based biotechnology company disclosed the sales data in a company announcement dated October 14, 2025. Genmab develops antibody therapeutics and has been operating for more than 25 years.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• Bank of America to redeem CAD1.425 billion in Canadian senior notes
• Alexander Dennis wins £57m Liverpool bus contract for 207 vehicles